Nanoscope Therapeutics Inc.
Ashish Patel serves as the Senior Vice President of Sales and Marketing at Nanoscope Therapeutics Inc., leading the commercial launch of retinal gene therapy MCO-010 since March 2025. Prior to this role, Ashish was the Vice President of Sales for IZERVAY at Iveric Bio from September 2021 to July 2024, where responsibilities included building and launching the sales function. Ashish also held various significant roles at Novartis, including Executive Director for BEOVU and Head of HCP Launch Marketing for brolucizumab. At Bayer, Ashish was instrumental as the Global Launch Lead for EYLEA and held positions in sales and brand management that positively impacted P&L. Earlier experience includes serving as a Senior Scientist in R&D at Novartis Pharmaceuticals. Ashish holds an MBA in Finance, Entrepreneurship, and Innovation from NYU Stern School of Business and a PhD in Physiology and Biophysics from Stony Brook University.
This person is not in any teams
This person is not in any offices
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa